Physicians' Academy for Cardiovascular Education

Novel therapies for the prevention of atherosclerotic vascular disease

Slides (presentation) - Oct. 8, 2012

Novel therapies for the prevention of atherosclerotic vascular disease

Selection of slides prepared & presented by:
Prof. John Kastelein, MD, Department of vascular medicine, Academic Medical Centre, Amsterdam, The Netherlands
at PACE Lipid Master Class
Budapest, September 21-22, 2012

View presentation, click on images

Novel therapies
Novel Approaches to Modify Lipids and Lipoproteins
Statin Prescription in the UK
Percentage of the UK-population
All-Cause Mortality in the UK
New Approaches to LDL Reduction
New Approaches to LDL Reduction
Heterozygous Familial Hypercholesterolemia
Mipomersen Significantly Reduced LDL-C
Distribution of LDL-C %
MTPIs – Efficacy comes
AEGR 733 HoFH Phase II Study Design
Change in Lipids Using Lomitapide
HoFH Phase 3: 6-Month Lipid Efficacy
LDL Receptor Function and Life Cycle
The Role of PCSK9
Impact of an Anti-PCSK9
Study Design REGN727
Changes in LDL-C
Change in Calculated LDL-C
Attainment of Prespecified LDL-C
Novel Approaches to Modify Lipids
New Approaches for Raising HDL
The Dal-HEART Program
25
Effects on LDL-C and HDL-C
Adjudicated CV Events and Death
Adjudicated CV Events and Death
Future
New Approaches for LDL and HDL
ApoA1 Based Therapies
New Approaches for Reduction of TG
Conclusion

Share this page with your colleagues and friends: